SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. However, if you've been treated with certain chemotherapy, antibiotics, or diuretics that cause hearing loss in the last 90 days, you cannot participate.
How does this drug differ from other treatments for splicing diseases?
This drug, RECTAS, is unique because it specifically targets and enhances the phosphorylation of splicing factors, which helps correct mis-splicing in genetic diseases like familial dysautonomia. Unlike other treatments, it directly interacts with cellular kinases to modulate splicing, offering a precision medicine approach to splicing disorders.12345
What is the purpose of this trial?
This trial tests SPI-1005, an oral medication, to prevent hearing loss and tinnitus in cancer patients receiving platinum-based chemotherapy. The treatment works by reducing harmful substances that can damage hearing.
Research Team
Jonathan Kil, MD
Principal Investigator
Sound Pharmaceuticals, Inc.
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive SPI-1005 or placebo orally twice daily for 3 days surrounding each cycle of platinum chemotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- SPI-1005
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sound Pharmaceuticals, Incorporated
Lead Sponsor
VA Puget Sound Health Care System
Collaborator